Testing effectiveness (Phase 2)Study completedNCT01591863
What this trial is testing
Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
Who this might be right for
Clostridium Difficile-associated Diarrhea
Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 38